Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate

利用首创抗体药物偶联物 DS-6157a 识别和靶向治疗胃肠道间质瘤中选择性表达的 GPR20

阅读：18

作者：Kenji Iida #, Amr H Abdelhamid Ahmed #, Akiko Kawano Nagatsuma, Tomoko Shibutani, Satoru Yasuda, Michiko Kitamura, Chiharu Hattori, Manabu Abe, Jun Hasegawa, Takuma Iguchi, Tsuyoshi Karibe, Takashi Nakada, Koichiro Inaki, Reiko Kamei, Yuki Abe, Taisei Nomura, Jessica L Andersen, Sandro Santagata, Ma

期刊：

Cancer Discovery

影响因子：

29.700

时间：

2021

起止号：

2021 Jun;11(6):1508-1523.

doi：

10.1158/2159-8290.CD-20-1434

方法学：

研究方向：

肿瘤

疾病类型：

胃癌

Significance

GPR20 is selectively expressed in GIST across all treatment lines, regardless of KIT/PDGFRA genotypes. We generated DS-6157a, a DXd-based antibody-drug conjugate that exhibited antitumor activity in GIST models by a different mode of action than currently approved TKIs, showing favorable pharmacokinetics and safety profiles.This article is highlighted in the In This Issue feature, p. 1307.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。